MGX
Metagenomi Therapeutics, Inc.Company with tickers: MGX
CIK
1785279
CUSIP
59102M104
Shares Outstanding
37,646,858
13F Activity (30d)
49 filings
47 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $4,127,000 | USD | 2025-03-31 | 10-Q | 2026-05-11 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $31,947,000 | USD | 2025-03-31 | 10-Q | 2026-05-11 |
| Research & Development | $25,142,000 | USD | 2025-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-27,820,000 | USD | 2025-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-25,039,000 | USD | 2025-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.68 | USD/shares | 2025-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.68 | USD/shares | 2025-03-31 | 10-Q | 2026-05-11 |